| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.034 | 0.4 |
| mRNA | PF-750 | CTRPv2 | pan-cancer | AAC | -0.036 | 0.4 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.045 | 0.4 |
| mRNA | ouabain | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | PF-4800567 hydrochloride | CTRPv2 | pan-cancer | AAC | 0.049 | 0.4 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.026 | 0.4 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | MS-275 | FIMM | pan-cancer | AAC | -0.14 | 0.4 |
| mRNA | Bicalutamide | FIMM | pan-cancer | AAC | 0.17 | 0.4 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | 0.18 | 0.4 |